Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Nearly 22,000 pounds of fentanyl were seized at US borders during the 2024 fiscal year, according to data from the US Customs ...

Medicare needs to cover non-opioid treatments instead of riskier ones. A new legislative proposal can help cover the cost.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

A new congressionally mandated report examines how opioid and benzodiazepine prescribing between 2007 and 2019 impacted ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...